Indications and results of radioiodine treatment of differentiated thyroid cancer

被引:0
|
作者
Riemann, B. [1 ]
机构
[1] Univ Klinikum Munster, Klin Nukl Med, Albert Schweitzer Campus 1, Munster, Germany
来源
CHIRURG | 2020年 / 91卷 / 12期
关键词
Risk profile; Prognosis; Side effects; Adjuvant treatment options; Interdisciplinary treatment concept; GUIDELINES;
D O I
10.1007/s00104-020-01248-x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Malignant tumors of the thyroid gland are the most frequent malignant endocrine neoplasms, comprising approximately 1% of all malignant tumors. In recent years there has been a clear rise in the incidence of differentiated thyroid carcinomas (DTC), especially small papillary carcinomas. Objective Indications for and results of radioiodine treatment (RAI) of DTC. Material and methods A review of the current literature and guidelines of RAI in DTC was carried out. Results The use of RAI is the most important adjuvant treatment option for DTC and is generally well-tolerated. Conclusion Due to the combination of surgery and RAI the DTC has a very good prognosis compared with other cancers, with an average survival rate of more than 90%.
引用
收藏
页码:1013 / 1016
页数:4
相关论文
共 50 条
  • [41] Radioiodine Treatment of Well-Differentiated Thyroid Cancer: Balancing Risks and Benefits
    Greenspan, Bennett S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18) : 1785 - +
  • [42] Bone metastases from differentiated thyroid cancer: Clinical features and radioiodine treatment
    Qiu, Zhong-ling
    Luo, Quan-yong
    Xu, Yan-hong
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [43] Physicians' preferences for radioiodine treatment of differentiated thyroid cancer in Brazil: an observational study
    Padovani, Rosalia do Prado
    Pansani, Isabella Fagian
    Marone, Marilia Martins Silveira
    Vaisman, Fernanda
    Maia, Ana Luiza Silva
    Dora, Jose Miguel Silva
    Ramos, Helton Estrela
    Hoff, Ana Amelia Fialho de Oliveira
    Coura Filho, George Barberio
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2024, 68
  • [44] Efficacy and safety of radioiodine in the treatment of disseminated differentiated thyroid cancer (DTC) in children
    Handkiewicz-Junak, D.
    Roskosz, J.
    Kropinska, A.
    Kozielski, J.
    Krzywiecki, A.
    Krajewska, J.
    Krajewska, J.
    Puch, Z.
    Olczyk, T.
    Jarzab, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Physicians' preferences for radioiodine treatment of differentiated thyroid cancer in Brazil: an observational study
    Padovani, Rosalia do Prado
    Pansani, Isabella Fagian
    Marone, Marilia Martins Silveira
    Vaisman, Fernanda
    Maia, Ana Luiza Silva
    Dora, Jose Miguel Silva
    Ramos, Helton Estrela
    Hoff, Ana Amelia Fialho de Oliveira
    Filho, George Barberio Coura
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2024, 68 : 1 - 14
  • [46] Treatment of radioiodine refractory high-differentiated thyroid cancer with lenvatinib.
    Romanov, Ilya
    Mudunov, Ali
    Isaev, Pavel
    Bychkov, Yury
    Odzharova, Akgul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer
    Maxon, HR
    Thomas, SR
    Samaratunga, RC
    [J]. THYROID, 1997, 7 (02) : 183 - 187
  • [48] Evaluation of radioiodine treatment of differentiated thyroid cancers with metastases
    Kücük, NÖ
    Aras, G
    Akin, A
    Erbay, G
    Ibis, E
    Kir, KM
    Tokuz, G
    Demir, H
    Gençoglu, EA
    Soylu, A
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1210 - 1210
  • [49] Challenges and strategies on radioiodine treatment for differentiated thyroid carcinoma
    Cheng, Lingxiao
    Liu, Min
    Ruan, Maomei
    Chen, Libo
    [J]. HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2016, 19 (01) : 23 - 32
  • [50] Radioiodine therapy in the different stages of differentiated thyroid cancer
    Valerio, Laura
    Maino, Fabio
    Castagna, Maria Grazia
    Pacini, Furio
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (01)